Q-omics provides the consensus-scored ZDHHC17 profile across patient tissues and cancer cell-line models. ZDHHC17 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, ZDHHC17 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ZDHHC17 RNA expression shows 21,201 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, HNSC, and UVM as cancer lineages where ZDHHC17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC17 survival associations across molecular data types. ZDHHC17 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC17 RNA expression–survival associations across cancer types. High ZDHHC17 expression shows unfavorable associations in LIHC, KIRP and CESC, but favorable associations in UCS, BRCA and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify UCS as the clearest survival context for ZDHHC17 RNA expression.
This table summarizes ZDHHC17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZDHHC17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC17 shows lower tumor expression in UCEC, BRCA and KICH and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher ZDHHC17 RNA expression in tumor versus normal tissue (log2 FC = +0.634, t-test p < 0.001).
This table shows molecular features associated with ZDHHC17 in patient tissues and cancer cell lines. In patient samples, ZDHHC17 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
